Column Group funds trim Tenaya Therapeutics (TNYA) with 829,734-share sale
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Column Group–affiliated investment funds, significant stockholders of Tenaya Therapeutics, reported open-market sales of an aggregate 829,734 shares of Common Stock on February 20 and 23. Reported weighted-average sale prices were about $0.61 per share, within disclosed ranges from $0.573 to $0.63.
The securities are held indirectly through entities including The Column Group III, LP, The Column Group III-A, LP and TCG Opportunity III LPPeter Svennilson and Tim Kutzkey, may be deemed to share voting and investment power but disclaim beneficial ownership except to the extent of their pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 829,734 shares ($504,787)
Net Sell
5 txns
Insider
COLUMN GROUP III GP, LP, COLUMN GROUP III, LP, COLUMN GROUP III-A, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Kutzkey Tim, Svennilson Peter
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Sold
829,734 shs ($505K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 143,709 | $0.5972 | $86K |
| Sale | Common Stock | 162,291 | $0.5972 | $97K |
| Sale | Common Stock | 245,965 | $0.6149 | $151K |
| Sale | Common Stock | 277,769 | $0.6149 | $171K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 1,958,509 shares (Indirect, See Footnote)
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.60 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.573 to $0.6225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
FAQ
What insider activity did Column Group entities report for Tenaya Therapeutics (TNYA)?
Column Group–affiliated funds reported selling 829,734 shares of Tenaya Therapeutics common stock in open-market transactions on February 20 and 23, 2026. All reported positions are held indirectly through investment partnerships described in the filing’s footnotes.
What does the weighted-average sale price disclosure mean for TNYA trades?
Weighted-average prices indicate that each reported transaction includes multiple individual trades at different prices within stated ranges. The reporting persons commit to provide full breakdowns of share counts at each specific price upon request to the issuer, security holders or SEC staff.